Clinical Trial Update: Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial evaluating atomoxetine for ADHD symptoms in adolescents with cannabis use disorder was terminated, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Cannabis Use Disorder

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder, Cannabis Abuse | Phase 4 | Status: TERMINATED | Results posted: 2010-08-19